Polyunsaturated fatty acid supplementation for schizophrenia

Joy, CB; Mumby-Croft, R.; Joy, L A

doi:10.1002/14651858.cd001257.pub2

Cited by 60 publications

(41 citation statements)

References 54 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent trial offers preliminary proof of this concept, reporting that 12 weeks of fish oil treatment might by itself, without any antipsychotic medication, protect APS syndrome patients from becoming psychotic for at least 12 months (Amminger et al, 2010), when findings in chronic patients are inconclusive (Irving et al, 2006). This treatment was studied without a goal of an FDA indication; however, such a pathway to wide use of a new treatment is unusual.…”

Section: Promoting Needed Treatment and Prevention Researchmentioning

confidence: 99%

The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome

Woods

Walsh

Saksa

et al. 2010

Schizophrenia Research

108

View full text Add to dashboard Cite

The American Psychiatric Association Task Force on DSM-5 has recently proposed consideration of Attenuated Psychotic Symptoms Syndrome as a new diagnosis, based on nearly 15 years of prospective research in centers across the globe. The condition is also known as "psychosis risk syndrome," "at-risk mental state," "ultra-high risk," and "putative prodrome." We review evidence favoring its inclusion as a new diagnosis in DSM-5 and report new preliminary findings on DSM-IV diagnoses in current clinical use for these patients and on results of diagnostic interviews in unselected volunteers.The main evidence supporting inclusion is: (1) the patients are currently ill, (2) the patients are at high risk for getting worse, (3) no DSM-IV diagnosis accurately captures their current illness or future risk, (4) the diagnosis has been made with reliability and validity in the research setting, and (5) placement in DSM-5 would help promote the needed treatment and prevention research to enable articulation of a standard of care to benefit these patients and their families. Potential harms can be minimized by patient, family, and provider education. It will be important to demonstrate through well-designed field trials whether the diagnostic criteria can be used with reliability in everyday clinical practice.

show abstract

Section: Promoting Needed Treatment and Prevention Researchmentioning

confidence: 99%

The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome

Woods

Walsh

Saksa

et al. 2010

Schizophrenia Research

108

View full text Add to dashboard Cite

show abstract

“…Other studies showed decreased polyunsaturated fatty acids in red blood cell membranes from patients with schizophrenia; the appropriateness of this finding was also supported by meta-analysis studies1112. In contrast, a Cochrane review13 indicated that the clinical effects polyunsaturated fatty acid administration for schizophrenia have been inconsistent. Hence, fatty acid disturbances might not be central to the etiology of schizophrenia.…”

mentioning

confidence: 93%

Decreased 16:0/20:4-phosphatidylinositol level in the post-mortem prefrontal cortex of elderly patients with schizophrenia

Matsumoto

Nakanishi

Kunii

et al. 2017

Sci Rep

View full text Add to dashboard Cite

The etiology of schizophrenia includes phospholipid abnormalities. Phospholipids are bioactive substances essential for brain function. To analyze differences in the quantity and types of phospholipids present in the brain tissue of patients with schizophrenia, we performed a global analysis of phospholipids in multiple brain samples using liquid chromatography electrospray ionization mass/mass spectrometry (LC-ESI/MS/MS) and imaging mass spectrometry (IMS). We found significantly decreased 16:0/20:4-phosphatidylinositol (PI) levels in the prefrontal cortex (PFC) in the brains from patients with schizophrenia in the LC-ESI/MS/MS, and that the 16:0/20:4-PI in grey matter was most prominently diminished according to the IMS experiments. Previous reports investigating PI pathology of schizophrenia did not identify differences in the sn-1 and sn-2 fatty acyl chains. This study is the first to clear the fatty acid composition of PI in brains from patients with schizophrenia. Alteration in the characteristic fatty acid composition of PI may also affect neuronal function, and could play a role in the etiology of schizophrenia. Although further studies are necessary to understand the role of reduced 16:0/20:4-PI levels within the prefrontal cortex in the etiology of schizophrenia, our results provide insight into the development of a novel therapy for the clinical treatment of schizophrenia.

show abstract

“…We would consider studies if they compared dietary advice with standard care (without dietary advice). We would not include studies if the dietary advice was given in combination with additional interventions such as exercise, or in conjunction with oral dietary supplements (including polyunsaturated fatty acid supplementation for schizophrenia (Irving 2006).…”

Section: Types Of Interventionsmentioning

confidence: 99%